PatientsVille.com Logo

Schizophrenia and Risperdal

PatientsVille

Schizophrenia Symptoms and Causes

Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves.

Symptoms of Schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get Schizophrenia after age 45. There are three types of symptoms:

  • Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements.
  • "Negative" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn.
  • Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.

No one is sure what causes Schizophrenia. Your genes, environment, and brain chemistry may play a role.

There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training.

NIH: National Institute of Mental Health

Check out the latest treatments for schizophrenia

schizophrenia treatment research studies

Risperdal clinical trials, surveys and public health registries


Find Drug Side Effect reports



Risperdal Side Effects

Weight Increased (453)
Suicide Attempt (403)
Diabetes Mellitus (381)
Self Injurious Behaviour (331)
Intentional Overdose (330)
Somnolence (292)
Aggression (259)
Death (250)
Overdose (223)
Tachycardia (218)
Fall (214)
Fatigue (187)
Neuroleptic Malignant Syndrome (183)
Psychotic Disorder (182)
Off Label Use (181)
Agitation (180)
Anxiety (178)
Suicidal Ideation (177)
Depression (173)
Abnormal Behaviour (171)
Extrapyramidal Disorder (170)
Insomnia (169)
Hospitalisation (169)
Convulsion (169)
Tremor (166)
Confusional State (158)
Dizziness (156)
Blood Prolactin Increased (156)
Leukopenia (154)
Tardive Dyskinesia (150)
Type 2 Diabetes Mellitus (144)
Treatment Noncompliance (144)
Pneumonia (143)
Hypotension (135)
Weight Decreased (127)
Hallucination (127)
Blood Creatine Phosphokinase Increased (126)
Pyrexia (125)
Myocardial Infarction (123)
Completed Suicide (123)
Dyspnoea (123)
Vomiting (122)
Hyponatraemia (122)
Dyskinesia (121)
Sedation (120)
Akathisia (120)
Asthenia (120)
Headache (117)
Gait Disturbance (117)
Dysphagia (116)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<span style='color: #808080;'><b>Describe Your Schizophrenia from HPV (GARDASIL) 2007 Experience Here:My 15 year old sonjust received first vaccination for HPV, nine days later experienced a psychotic disorder for one week, now

Is it ok to take Valerian with Risperadal (I take 1.5 mg a day)?

Went from 96 lbs to 170 lbs in a few short months. Haven't been able to lose any of the weight. I no longer have periods either. Haven't had one since 08. I'm writing this comment in May of 2010. Besi

<span style='color: #808080;'><b>Describe Your Schizophrenia from HPV (GARDASIL) 2007 Experience Here:My 15 year old sonjust received first vaccination for HPV, nine days later experienced a psychotic disorder for one week, now

Hi! I've been taking 50-100mg of solian/ amisulpride and I have been in remission of schizophrenia for years on it. I don't get any bad side effects and i get the pleasant side effect of euphoria on it. It's taken me years to find solian, and the oth

I have been on Clopixol since 5 years and it has solved my problem (a mild form of schizophrenia), I heard voices and was a little bit too aggressive. But now I've put on these 10 kgs...

I have been prescribed Haloperidol for my acne. I have come to know that this is a drug for Schizophrenia - Why is this drug prescribed to me by my dermatologist ? Should I stop or continue ?

I just begun to take zeldox and I like it because my other pills made me sick. I noticed that I feel relaxed, sleepy and less nervous. I have schizophrenia, which i think i read somewhere is related to Parkinsons (dangerous!), so i like the pills.

I was on resperidone 4mg as well as Seriquel 600mg and i gained about 60 pounds on them so i stopped them as well and ended up in the hospital and they started me on the zeldox. Its helping my schizophrenia but its making me exhausted and not sleep a

My Mom was given Nuvigil for approximately six months. After stopping the drug, she has developed psychotic symptoms. She has recently been hospitalized and diagnosed with paranoid schizophrenia. She is 59 years old and never had any psychosis bef

My mother is suffering from schizophrenia, i found her not mentally satisfied not everything looking good to her still she holds the whole house but sometimes she feels like restless....

Safest antidepressant in conjuction with Amisulpride for treatment of depression associated with Schizophrenia. Thanks

Schizophrenia Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
Condition: Negative Symptoms of Schizophrenia in Post-menopausal Women.
Interventions: Drug: Raloxifene;   Drug: Lactosa (placebo arm)
Outcome Measures: To assess the efficacy of raloxifene (SERM - Selective Estrogen Receptor Modulator) as an adjuvant of antipsychotic treatment in the management of negative symptoms of Schizophrenia in post-menopausal women.;   To assess the efficacy of raloxifene as an adjuvant of antipsychotic treatment in the management of global symptoms of Schizophrenia in postmenopausal women.;   To assess the efficacy of raloxifene as an adjuvant of antipsychotic treatment in the global functioning of postmenopausal women with Schizophrenia.;   To assess the efficacy of raloxifene as an adjuvant of antipsychotic treatment in the neuropsychological functioning of post-menopausal women with Schizophrenia;   To control response to treatment as a function of genetic variants in the form of SNP (Single Nucleotide Polymorphisms) that patients present in the alfa (ESR1) and beta (ESR2) estrogenic receptor genes.;   To assess the safety of the medication used in this patient population.
2 Unknown  Evaluation of Mirtazapine and Folic Acid for Schizophrenia:
Conditions: Schizophrenia;   Negative Symptoms
Interventions: Drug: mirtazapine and folic acid;   Drug: mirtazapine, folic acid placebo;   Drug: mirtazapine placebo, folic acid;   Drug: mirtazapine placebo, folic acid placebo
Outcome Measures: To compare the efficacy of mirtazapine and placebo for treatment of symptoms associated with Schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of symptoms of Schizophrenia;   To compare the efficacy of mirtazapine and placebo for treatment of negative symptoms of Schizophrenia;   To compare the efficacy of folic acid and placebo for treatment of negative symptoms of Schizophrenia;   To compare the safety and tolerability of mirtazapine and placebo in patients with Schizophrenia;   To compare the safety and tolerability of folic acid and placebo in patients with Schizophrenia
3 Unknown  Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Intervention: Drug: D-serine
Outcome Measures: SANS - Scale for the Assessment of Negative Symptoms - weeks 0, 8 and 16;   Measurement and Treatment Research for Cognition in Schizophrenia (MATRICS) battery - visit weeks 0, 8 and 16;   Positive and Negative Syndrome Scale of Schizophrenia (PANSS) positive, negative, general and total score - weeks 0, 8 and 16;   Simpson-Angus Scale (SAS) total score - weeks 0, 8 and 16;   Clinical Global Impressions (CGI) score - weeks 0, 8 and 16;   Calgary Depression Scale for Schizophrenia (CDSS) score - weeks 0, 8 and 16;   Side effect check list
4 Not yet recruiting Multi-site Communication Deficits in Schizophrenia
Conditions: Schizophrenia;   Psychosis
Intervention:
Outcome Measure:
5 Recruiting Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Intervention: Drug: Varenicline
Outcome Measures: Computerized testing of neuropsychological functioning;   Tiffany Urge to Smoke Scale;   Minnesota Withdrawal Scale;   Pre-pulse inhibition;   Smoking topography
6 Recruiting Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: a Combined Transcranial Magnetic Stimulation and Electroencephalography Study Across the Life Span
Condition: Schizophrenia
Intervention: Other: Brain Stimulation via Transcranial Magnetic Stimulation
Outcome Measure: Changes in working memory
7 Recruiting Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)
Condition: Depression
Intervention:
Outcome Measures: The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in Schizophrenia patients.;   The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in Schizophrenia patients.;   The prevalence of depression in patients with Schizophrenia;   The association between depression in Schizophrenia and quality of life.;   The association between depression in Schizophrenia and type of antipsychotic drugs.;   The association between depression in Schizophrenia and severity of Schizophrenia.
8 Recruiting Psychosis-Associated Neuroinflammation in Schizophrenia
Conditions: Schizophrenia;   Psychosis
Interventions: Radiation: [18F]-PBR111 Positron Emission Tomography (PET);   Behavioral: Cognitive and psychomotor tasks;   Biological: Blood sampling
Outcome Measures: Regional VT of [18F]PBR111;   Peripheral markers
9 Unknown  D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
Condition: Schizophrenia
Interventions: Drug: D-cycloserine;   Drug: Placebo;   Behavioral: Cognitive Remediation
Outcome Measures: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS);   Positive and Negative Syndrome Scale (PANSS);   Scale for Assessment of Negative Symptoms (SANS);   Global Assessment Scale (GAS);   Heinrich Quality of Life Scale (QoL);   Calgary Depression Scale for Schizophrenia (CDSS);   Clinical Global Impression (CGI);   Side Effects Checklist (SEC);   Brain Fitness Program Processing Speed Assessment
10 Recruiting Prospective Studies of the Pathogenesis of Schizophrenia
Condition: Schizophrenia
Intervention:
Outcome Measures: magnetic resonance images (structural and functional);   Cognitive development
11 Unknown  Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Intervention: Behavioral: Family-Directed Cognitive Adaptation Program
Outcome Measures: All of the following are measured at baseline, post-intervention,;   and 3 and 6-month follow up;   Social Adaptive Functions Scale (P);   Multnomah Community Ability Scale (P);   Global Assessment of Functioning (P);   F= Family measure P= Patient measure;   BPRS, PANSS (P);   SANS (P);   Interpersonal Affectivity Scale (P, F);   Knowledge Questionnaire (P, F);   Independent Living Skills Survey (P, F);   Ind Living Self Care Checklist (P, F);   Frontal Lobe Personality Scale (P, F);   Clinical Global Impression of Cognition in Schizophrenia (P, F);   Patient Rejection Scale (F);   Modified Family Resources Interview (F);   Modified Schizophrenia Knowledge Scale (F);   Family Self-Efficacy Scale (F);   Caregiving Gains and Benefits/ Gratifications Module (F);   Beck Depression and Anxiety Inventories (F);   This measure is completed post-intervention only:;   Client Satisfaction Questionnaire (P, F)
12 Recruiting Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
Conditions: Schizophrenia;   Anxiety-comorbidity to Schizophrenia
Interventions: Drug: Pregabalin;   Drug: Pregabalin Placebo Capsules
Outcome Measures: Hamilton Anxiety Scale;   UKU-Overall adverse effect scale
13 Not yet recruiting Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Behavioral: Cognitive remediation training;   Drug: Nicotine polacrilex lozenge
Outcome Measures: Change in MATRICS Consensus Cognitive Battery (MCCB) score;   Progression in training exercise parameters;   Change in Brief Psychiatric Rating Scale (BPRS) score;   Change in Scale for the Assessment of Negative Symptoms (SANS) score;   Change in Calgary Depression Scale score;   Change in UCSD Performance-Based Skills Assessment (UPSA) score;   Change in Abbreviated Schizophrenia Quality of Life Scale score;   Change in Cognitive Assessment Interview (CAI) score;   Change in Working memory capacity
14 Unknown  Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
Condition: Schizophrenia
Intervention: Dietary Supplement: Sarcosine
Outcome Measures: Assessment of sarcosine vs. placebo impact on Schizophrenia symptoms using Positive and Negative Syndrome Scale (PANSS).;   Impact assessment of sarcosine versus placebo on the parameters of quality of life (QoL) and sexual functioning.;   Impact assessment of sarcosine versus placebo on depressive symptoms using Calgary Depression Scale for Schizophrenia.;   Impact assessment of sarcosine versus placebo on cognitive functions using Wisconsin Card Sort Test, Trail Making Test and Stroop Test.;   Impact assessment of sarcosine versus placebo on oxidative stress parameters (T-BARS).;   Impact assessment of sarcosine versus placebo on brain metabolism parameters (magnetic resonance spectroscopy).;   Impact assessment of sarcosine versus placebo on oculomotoric parameters (saccadic and antisaccadic task in electrooculography).;   Impact assessment of sarcosine versus placebo on blood levels of glycine, sarcosine, BDNF and MMP-9.
15 Recruiting Clozapine for Cannabis Use in Schizophrenia
Conditions: Schizophrenia;   Cannabis Abuse;   Cannabis Dependence;   Dual Diagnosis
Interventions: Drug: Clozapine;   Drug: Risperidone
Outcome Measures: Intensity of cannabis use;   Frequency of cannabis use;   Symptoms of Schizophrenia;   Quality of Life;   Neuropsychological functioning;   Reward responsiveness
16 Recruiting Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia
Conditions: Childhood Onset Psychotic Disorders;   Schizophrenia;   Psychosis;   Mental Disorders Mental Disorder Diagnosed in Childhood
Intervention: Behavioral: Electrical Polarization
Outcome Measures: TDCS treatment is safe in childhood onset Schizophrenia;   Improvement in cognition and psychosis
17 Recruiting Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia
Condition: Genetic High Risk for Schizophrenia
Intervention:
Outcome Measures: Structural and functional characteristics of neurons differentiated from adipose tissue derived stem cells in subjects with genetic high risk for Schizophrenia and healthy controls;   CAARMS(Comprehensive assessment of at risk mental states);   PANSS(Positive and Negative Syndrome Scale);   Neurocognitive function test battery (composite);   ERP(event-related potential) profile;   Structural/resting functional MRI data;   Proton MR spectroscopy;   PET imaging data
18 Unknown  Role of Anti-Inflammatory Agents in Patients With Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Psychosis Not Otherwise Specified;   Schizophreniform Disorder
Interventions: Drug: Ondansetron;   Drug: Simvastatin;   Drug: Placebo
Outcome Measures: acceptability and tolerability of simvastatin and ondansetron added to TAU;   simvastatin and ondansetron added to TAU prevents the accumulation of negative symptoms in patients with Schizophrenia;   simvastatin and ondansetron added to TAU prevents cognitive decline;   To compare the effect size
19 Recruiting Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia
Conditions: Refractory Schizophrenia;   Super Refractory Schizophrenia
Interventions: Device: MECTA SPECTRUM 5000Q ECT;   Procedure: Sham ECT
Outcome Measures: PANSS change from baseline;   CGI change from baseline
20 Recruiting Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
Condition: Schizophrenia
Interventions: Drug: sarcosine;   Drug: sarcosine+ BE;   Drug: placebo
Outcome Measures: Positive, negative, cognitive symptoms of Schizophrenia, laboratory tests.;   The subscales of PANSS,MATRICAS, and serum DAAO levels.